Biopharmaceuticals Contract Manufacturing Market Size, Share, Trends, and Growth Outlook

Biopharmaceuticals Contract Manufacturing Market is estimated to increase at a growth rate of 5.6% CAGR over the forecast period from 2024 to 2030.

 

The Biopharmaceuticals Contract Manufacturing Market study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments including By Source (Mammalian, Non-mammalian), By Service (Process Development, Fill & Finish Operations, Analytical & QC studies, Packaging), By Product (Biologics, BiosimilarsOthers), By Therapeutic Area (Oncology, Autoimmune Diseases, Metabolic Diseases, Cardiovascular Diseases, Neurology, Infectious Diseases, Others).

 

An Introduction to Biopharmaceuticals Contract Manufacturing Market in 2024

The Biopharmaceuticals Contract Manufacturing market in 2024 provides essential outsourcing services to biotechnology and pharmaceutical companies seeking to scale up production, reduce manufacturing costs, and accelerate time to market for biologic drugs. Contract manufacturing organizations (CMOs) specializing in biopharmaceuticals offer expertise in cell culture, fermentation, purification, and fill-finish operations to produce a wide range of biologic therapeutics, including monoclonal antibodies, recombinant proteins, vaccines, and gene therapies. By leveraging state-of-the-art facilities, regulatory compliance, and technical expertise, biopharmaceuticals CMOs enable clients to overcome manufacturing challenges, mitigate risks, and focus on core competencies such as research, development, and commercialization. As the biopharmaceutical industry continues to grow and diversify, fueled by advancements in biotechnology and personalized medicine, the demand for contract manufacturing services is increasing, driving growth and innovation in the biopharmaceuticals contract manufacturing market.

Biopharmaceuticals Contract Manufacturing Market Trend: Increased Outsourcing of Biopharmaceutical Manufacturing

A prominent trend in the Biopharmaceuticals Contract Manufacturing market is the increased outsourcing of biopharmaceutical manufacturing by pharmaceutical companies. As the demand for biologic drugs continues to rise due to their effectiveness in treating various diseases, pharmaceutical companies are facing challenges in scaling up production capacities and maintaining flexibility in manufacturing processes. Outsourcing manufacturing to contract manufacturing organizations (CMOs) allows pharmaceutical companies to leverage the expertise and specialized facilities of CMOs, enabling them to focus on their core competencies such as research and development (R&D) and commercialization. This trend is driving the growth of the biopharmaceuticals contract manufacturing market globally.

Biopharmaceuticals Contract Manufacturing Market Driver: Cost Efficiency and Time Savings

A key driver for the Biopharmaceuticals Contract Manufacturing market is the cost efficiency and time savings offered by outsourcing manufacturing to CMOs. Building and maintaining in-house manufacturing facilities for biopharmaceuticals require significant capital investment and resources. By partnering with CMOs, pharmaceutical companies can avoid these upfront costs and benefit from the economies of scale achieved by CMOs through their optimized manufacturing processes and infrastructure. Additionally, outsourcing manufacturing allows pharmaceutical companies to accelerate the development timeline for their products, enabling faster market entry and revenue generation.

Biopharmaceuticals Contract Manufacturing Market Opportunity: Expansion of Biologics Pipeline and Emerging Markets

One potential opportunity in the Biopharmaceuticals Contract Manufacturing market lies in the expansion of the biologics pipeline and the growing demand for contract manufacturing services in emerging markets. With advancements in biotechnology and the increasing prevalence of complex diseases, there is a growing pipeline of biologic drugs in various therapeutic areas such as oncology, autoimmune diseases, and infectious diseases. This expanding pipeline presents a significant opportunity for CMOs to collaborate with pharmaceutical companies in manufacturing biologic drugs, thereby driving market growth. Furthermore, the rising demand for biopharmaceuticals in emerging markets, fueled by improving healthcare infrastructure and growing healthcare expenditure, creates opportunities for CMOs to establish partnerships and expand their presence in these regions, catering to the manufacturing needs of local and multinational pharmaceutical companies.

 

Biopharmaceuticals Contract Manufacturing Market Segmentation

By Source

Mammalian

Non-mammalian

 

By Service

Process Development

-Downstream

-Upstream

Fill & Finish Operations

Analytical & QC studies

Packaging

 

By Product

Biologics

-Monoclonal antibodies (MABs)

-Recombinant Proteins

-Vaccines

-Antisense, RNAi, & Molecular Therapy

-Others

Biosimilars

Others

 

By Therapeutic Area

Oncology

Autoimmune Diseases

Metabolic Diseases

Cardiovascular Diseases

Neurology

Infectious Diseases

Others

 

Geographical Analysis

North America (United States, Canada, Mexico)

Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)

Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)

South America (Brazil, Argentina, Rest of South America)

Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)

 

Biopharmaceuticals Contract Manufacturing Market Companies

Boehringer Ingelheim GmbH

Lonza Group

Inno Biologics Sdn Bhd

Rentschler Biotechnologie GmbH

JRS Pharma (Celonic)

Samsung BioLogics

WuXi Biologics

AGC Biologics

ProBioGen AG

FUJIFILM Diosynth Biotechnologies USA Inc

INCOG BioPharma Services

Pressure BioSciences

*- List Not Exhaustive

 

Reasons to Buy the Biopharmaceuticals Contract Manufacturing Market Study

• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions

• Gain access to detailed insights on the Biopharmaceuticals Contract Manufacturing Market, encompassing current market size, growth trends, and forecasts till 2030.

• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities

• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends

• Identify lucrative investment avenues and expansion opportunities within the Biopharmaceuticals Contract Manufacturing Market industry, guided by robust, data-backed analysis.

• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics

• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain

• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics

• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.

TABLE OF CONTENTS

 

1 Introduction to 2024 Biopharmaceuticals Contract Manufacturing Market

1.1 Market Overview

1.2 Quick Facts

1.3 Scope/Objective of the Study

1.4 Market Definition

1.5 Countries and Regions Analyzed

1.6 Units, Currency, and Conversions

1.7 Industry Value Chain

 

2 Research Methodology

2.1 Market Size Estimation

2.2 Sources and Research Methodology

2.3 Data Triangulation

2.4 Assumptions and Limitations

 

3 Executive Summary

3.1 Global Biopharmaceuticals Contract Manufacturing Market Size Outlook, $ Million, 2021 to 2030

3.2 Biopharmaceuticals Contract Manufacturing Market Outlook by Type, $ Million, 2021 to 2030

3.3 Biopharmaceuticals Contract Manufacturing Market Outlook by Product, $ Million, 2021 to 2030

3.4 Biopharmaceuticals Contract Manufacturing Market Outlook by Application, $ Million, 2021 to 2030

3.5 Biopharmaceuticals Contract Manufacturing Market Outlook by Key Countries, $ Million, 2021 to 2030

 

4 Market Dynamics

4.1 Key Driving Forces of Biopharmaceuticals Contract Manufacturing Market Industry

4.2 Key Market Trends in Biopharmaceuticals Contract Manufacturing Market Industry

4.3 Potential Opportunities in Biopharmaceuticals Contract Manufacturing Market Industry

4.4 Key Challenges in Biopharmaceuticals Contract Manufacturing Market Industry

 

5 Market Factor Analysis

5.1 Competitive Landscape

5.1.1 Global Biopharmaceuticals Contract Manufacturing Market Share by Company (%), 2023

5.1.2 Product Offerings by Company

5.2 Porter’s Five Forces Analysis

 

6 Growth Outlook Across Scenarios

6.1 Growth Analysis-Case Scenario Definitions

6.2 Low Growth Scenario Forecasts

6.3 Reference Growth Scenario Forecasts

6.4 High Growth Scenario Forecasts

 

7 Global Biopharmaceuticals Contract Manufacturing Market Outlook By Segments

7.1 Biopharmaceuticals Contract Manufacturing Market Outlook by Segments

By Source

Mammalian

Non-mammalian

By Service

Process Development

-Downstream

-Upstream

Fill & Finish Operations

Analytical & QC studies

Packaging

By Product

Biologics

-Monoclonal antibodies (MABs)

-Recombinant Proteins

-Vaccines

-Antisense, RNAi, & Molecular Therapy

-Others

Biosimilars

Others

By Therapeutic Area

Oncology

Autoimmune Diseases

Metabolic Diseases

Cardiovascular Diseases

Neurology

Infectious Diseases

Others

 

8 North America Biopharmaceuticals Contract Manufacturing Market Analysis And Outlook To 2030

8.1 Introduction to North America Biopharmaceuticals Contract Manufacturing Markets in 2024

8.2 North America Biopharmaceuticals Contract Manufacturing Market Size Outlook by Country, 2021-2030

8.2.1 United States

8.2.2 Canada

8.2.3 Mexico

8.3 North America Biopharmaceuticals Contract Manufacturing Market size Outlook by Segments, 2021-2030

By Source

Mammalian

Non-mammalian

By Service

Process Development

-Downstream

-Upstream

Fill & Finish Operations

Analytical & QC studies

Packaging

By Product

Biologics

-Monoclonal antibodies (MABs)

-Recombinant Proteins

-Vaccines

-Antisense, RNAi, & Molecular Therapy

-Others

Biosimilars

Others

By Therapeutic Area

Oncology

Autoimmune Diseases

Metabolic Diseases

Cardiovascular Diseases

Neurology

Infectious Diseases

Others

 

9 Europe Biopharmaceuticals Contract Manufacturing Market Analysis And Outlook To 2030

9.1 Introduction to Europe Biopharmaceuticals Contract Manufacturing Markets in 2024

9.2 Europe Biopharmaceuticals Contract Manufacturing Market Size Outlook by Country, 2021-2030

9.2.1 Germany

9.2.2 France

9.2.3 Spain

9.2.4 United Kingdom

9.2.4 Italy

9.2.5 Russia

9.2.6 Norway

9.2.7 Rest of Europe

9.3 Europe Biopharmaceuticals Contract Manufacturing Market Size Outlook By Segments, 2021-2030

By Source

Mammalian

Non-mammalian

By Service

Process Development

-Downstream

-Upstream

Fill & Finish Operations

Analytical & QC studies

Packaging

By Product

Biologics

-Monoclonal antibodies (MABs)

-Recombinant Proteins

-Vaccines

-Antisense, RNAi, & Molecular Therapy

-Others

Biosimilars

Others

By Therapeutic Area

Oncology

Autoimmune Diseases

Metabolic Diseases

Cardiovascular Diseases

Neurology

Infectious Diseases

Others

 

10 Asia Pacific Biopharmaceuticals Contract Manufacturing Market Analysis And Outlook To 2030

10.1 Introduction to Asia Pacific Biopharmaceuticals Contract Manufacturing Markets in 2024

10.2 Asia Pacific Biopharmaceuticals Contract Manufacturing Market Size Outlook by Country, 2021-2030

10.2.1 China

10.2.2 India

10.2.3 Japan

10.2.4 South Korea

10.2.5 Indonesia

10.2.6 Malaysia

10.2.7 Australia

10.2.8 Rest of Asia Pacific

10.3 Asia Pacific Biopharmaceuticals Contract Manufacturing Market size Outlook by Segments, 2021-2030

By Source

Mammalian

Non-mammalian

By Service

Process Development

-Downstream

-Upstream

Fill & Finish Operations

Analytical & QC studies

Packaging

By Product

Biologics

-Monoclonal antibodies (MABs)

-Recombinant Proteins

-Vaccines

-Antisense, RNAi, & Molecular Therapy

-Others

Biosimilars

Others

By Therapeutic Area

Oncology

Autoimmune Diseases

Metabolic Diseases

Cardiovascular Diseases

Neurology

Infectious Diseases

Others

 

11 South America Biopharmaceuticals Contract Manufacturing Market Analysis And Outlook To 2030

11.1 Introduction to South America Biopharmaceuticals Contract Manufacturing Markets in 2024

11.2 South America Biopharmaceuticals Contract Manufacturing Market Size Outlook by Country, 2021-2030

11.2.1 Brazil

11.2.2 Argentina

11.2.3 Rest of South America

11.3 South America Biopharmaceuticals Contract Manufacturing Market size Outlook by Segments, 2021-2030

By Source

Mammalian

Non-mammalian

By Service

Process Development

-Downstream

-Upstream

Fill & Finish Operations

Analytical & QC studies

Packaging

By Product

Biologics

-Monoclonal antibodies (MABs)

-Recombinant Proteins

-Vaccines

-Antisense, RNAi, & Molecular Therapy

-Others

Biosimilars

Others

By Therapeutic Area

Oncology

Autoimmune Diseases

Metabolic Diseases

Cardiovascular Diseases

Neurology

Infectious Diseases

Others

 

12 Middle East And Africa Biopharmaceuticals Contract Manufacturing Market Analysis And Outlook To 2030

12.1 Introduction to Middle East and Africa Biopharmaceuticals Contract Manufacturing Markets in 2024

12.2 Middle East and Africa Biopharmaceuticals Contract Manufacturing Market Size Outlook by Country, 2021-2030

12.2.1 Saudi Arabia

12.2.2 UAE

12.2.3 Oman

12.2.4 Rest of Middle East

12.2.5 Egypt

12.2.6 Nigeria

12.2.7 South Africa

12.2.8 Rest of Africa

12.3 Middle East and Africa Biopharmaceuticals Contract Manufacturing Market size Outlook by Segments, 2021-2030

By Source

Mammalian

Non-mammalian

By Service

Process Development

-Downstream

-Upstream

Fill & Finish Operations

Analytical & QC studies

Packaging

By Product

Biologics

-Monoclonal antibodies (MABs)

-Recombinant Proteins

-Vaccines

-Antisense, RNAi, & Molecular Therapy

-Others

Biosimilars

Others

By Therapeutic Area

Oncology

Autoimmune Diseases

Metabolic Diseases

Cardiovascular Diseases

Neurology

Infectious Diseases

Others

 

13 Company Profiles

13.1 Company Snapshot

13.2 SWOT Profiles

13.3 Products and Services

13.4 Recent Developments

13.5 Financial Profile

List of Companies

Boehringer Ingelheim GmbH

Lonza Group

Inno Biologics Sdn Bhd

Rentschler Biotechnologie GmbH

JRS Pharma (Celonic)

Samsung BioLogics

WuXi Biologics

AGC Biologics

ProBioGen AG

FUJIFILM Diosynth Biotechnologies USA Inc

INCOG BioPharma Services

Pressure BioSciences

 

14 Appendix

14.1 Customization Offerings

14.2 Subscription Services

14.3 Related Reports

14.4 Publisher Expertise

Biopharmaceuticals Contract Manufacturing Market Segmentation

By Source

Mammalian

Non-mammalian

 

By Service

Process Development

-Downstream

-Upstream

Fill & Finish Operations

Analytical & QC studies

Packaging

 

By Product

Biologics

-Monoclonal antibodies (MABs)

-Recombinant Proteins

-Vaccines

-Antisense, RNAi, & Molecular Therapy

-Others

Biosimilars

Others

 

By Therapeutic Area

Oncology

Autoimmune Diseases

Metabolic Diseases

Cardiovascular Diseases

Neurology

Infectious Diseases

Others

 

Geographical Analysis

North America (United States, Canada, Mexico)

Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)

Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)

South America (Brazil, Argentina, Rest of South America)

Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)